The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparison

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|2|219-226

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.2, 2015-03, pp. : 219-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 766-771

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epsilon-Aminocaproic Acid Inhibits the Activity of Factor VIII Inhibitors in Patients with Severe Haemophilia A in vivo and in vitro

By  

Acta Haematologica, Vol. 103, Iss. 2, 2000-05 ,pp. : 67-72

Karger

Access to resources Recommend Favorite

An ELISA Assay for the Detection of Factor VIII Antibodies – Comparison with the Conventional Bethesda Assay in a Large Cohort of Haemophilia Samples

By  

Acta Haematologica, Vol. 109, Iss. 1, 2002-12 ,pp. : 18-22

Karger

Access to resources Recommend Favorite

Factor VIII Inhibitors in Two Families with Mild Haemophilia A: Structural Analysis of the Mutations

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 30, Iss. 5, 2001-03 ,pp. : 268-279

Karger

Access to resources Recommend Favorite

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 16, Iss. 2, 2018-02 ,pp. : 303-315

John Wiley & Sons Inc

Access to resources Recommend Favorite